137 related articles for article (PubMed ID: 33786682)
1. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
[TBL] [Abstract][Full Text] [Related]
2. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
[TBL] [Abstract][Full Text] [Related]
3. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
4. Three molecular subtypes and a five-gene signature for hepatocellular carcinoma based on m7G-related classification.
Yue Y; Tao J; An D; Shi L
J Gene Med; 2024 Jan; 26(1):e3611. PubMed ID: 37847055
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell proliferation.
Tang S; Sun R; Tang K; Wei X; Liu M; Zhang H
Clin Transl Oncol; 2024 Jun; 26(6):1368-1383. PubMed ID: 38123874
[TBL] [Abstract][Full Text] [Related]
6. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma.
Xie Z; Huang J; Li Y; Zhu Q; Huang X; Chen J; Wei C; Luo S; Yang S; Gao J
Sci Rep; 2023 Nov; 13(1):18799. PubMed ID: 37914817
[TBL] [Abstract][Full Text] [Related]
8. Recurrence risk stratification of hepatocellular carcinomas based on immune gene expression and features extracted from pathological images.
Ding T; Li X; Mo J; Alexander G; Li J
PLoS Comput Biol; 2023 Dec; 19(12):e1011716. PubMed ID: 38157378
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.
Ho DW; Tsui YM; Chan LK; Sze KM; Zhang X; Cheu JW; Chiu YT; Lee JM; Chan AC; Cheung ET; Yau DT; Chia NH; Lo IL; Sham PC; Cheung TT; Wong CC; Ng IO
Nat Commun; 2021 Jun; 12(1):3684. PubMed ID: 34140495
[TBL] [Abstract][Full Text] [Related]
10. Identification of molecular subtypes and prognostic signatures based on transient receptor potential channel-related genes to predict the prognostic risk of hepatocellular carcinoma: A review.
Wu D; Cai Q; Liu D; Zuo G; Li S; Liu L; Zheng J
Medicine (Baltimore); 2023 Mar; 102(10):e33228. PubMed ID: 36897679
[TBL] [Abstract][Full Text] [Related]
11. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma.
Liu F; Qin L; Liao Z; Song J; Yuan C; Liu Y; Wang Y; Xu H; Zhang Q; Pei Y; Zhang H; Pan Y; Chen X; Zhang Z; Zhang W; Zhang B
Exp Hematol Oncol; 2020; 9():10. PubMed ID: 32509418
[TBL] [Abstract][Full Text] [Related]
12. Identification of Proteome-Based Immune Subtypes of Early Hepatocellular Carcinoma and Analysis of Potential Metabolic Drivers.
Diao L; He M; Xu B; Chen L; Wang Z; Yang Y; Xia S; Hu S; Guo S; Li D
Mol Cell Proteomics; 2024 Jan; 23(1):100686. PubMed ID: 38008179
[TBL] [Abstract][Full Text] [Related]
13. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.
Xing X; Hu E; Ouyang J; Zhong X; Wang F; Liu K; Cai L; Zhou Y; Wang Y; Chen G; Li Z; Wu L; Liu X
Cell Rep Med; 2023 Dec; 4(12):101315. PubMed ID: 38091986
[TBL] [Abstract][Full Text] [Related]
14. Deconvolution of immune cell composition and biological age of hepatocellular carcinoma using DNA methylation.
Jain SS; McNamara ME; Varghese RS; Ressom HW
Methods; 2023 Oct; 218():125-132. PubMed ID: 37574160
[TBL] [Abstract][Full Text] [Related]
15. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.
Sun Y; Wu P; Zhang Z; Wang Z; Zhou K; Song M; Ji Y; Zang F; Lou L; Rao K; Wang P; Gu Y; Gu J; Lu B; Chen L; Pan X; Zhao X; Peng L; Liu D; Chen X; Wu K; Lin P; Wu L; Su Y; Du M; Hou Y; Yang X; Qiu S; Shi Y; Sun H; Zhou J; Huang X; Peng DH; Zhang L; Fan J
Cancer Cell; 2024 Jan; 42(1):135-156.e17. PubMed ID: 38101410
[TBL] [Abstract][Full Text] [Related]
16. SIMarker: Cellular similarity detection and its application to diagnosis and prognosis of liver cancer.
Tong M; Luo S; Gu L; Wang X; Zhang Z; Liang C; Huang H; Lin Y; Huang J
Comput Biol Med; 2024 Mar; 171():108113. PubMed ID: 38368754
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis Shows Enrichment of Macrophages, Overexpression of Checkpoint Molecules, Inhibitory Cytokines, and Immune Exhaustion Signatures in EMT-High Tumors.
Tiwari JK; Negi S; Kashyap M; Nizamuddin S; Singh A; Khattri A
Front Oncol; 2021; 11():793881. PubMed ID: 35096592
[TBL] [Abstract][Full Text] [Related]
18. N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes.
DelaCourt A; Black A; Angel P; Drake R; Hoshida Y; Singal A; Lewin D; Taouli B; Lewis S; Schwarz M; Fiel MI; Mehta AS
Mol Cancer Res; 2021 Nov; 19(11):1868-1877. PubMed ID: 34380744
[TBL] [Abstract][Full Text] [Related]
19. Identification of the new molecular subtypes related to inflammation in breast cancer.
Yu K; Xu C; Wang F; Wang H
Medicine (Baltimore); 2024 May; 103(19):e38146. PubMed ID: 38728446
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology.
Okrah K; Tarighat S; Liu B; Koeppen H; Wagle MC; Cheng G; Sun C; Dey A; Chang MT; Sumiyoshi T; Mounir Z; Cummings C; Hampton G; Amler L; Fridlyand J; Hegde PS; Turley SJ; Lackner MR; Huang SM
NPJ Precis Oncol; 2018; 2():25. PubMed ID: 30456308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
